Literature DB >> 19429435

Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells.

Orazia M Granata1, Letizia Cocciadifero, Ildegarda Campisi, Vitale Miceli, Giuseppe Montalto, Lucia M Polito, Biagio Agostara, Giuseppe Carruba.   

Abstract

There is indirect multiple evidence that hints at a potential role of sex steroids in development and progression of human hepatocellular carcinoma (HCC). In the present study, we have investigated androgen metabolism in a panel of human liver cancer cell lines (HA22T, Huh7, HepG2) and in normal, cirrhotic and malignant human liver tissues aiming to dissect the potential impact of individual enzyme activities and their products in normal and diseased human liver, both in vivo and in vitro. Using our intact cell analysis we were able to assess rates and pathways of androgen metabolism in living conditions. Overall, incubation of cultured cells or tissue minces with either testosterone (T) or androstenedione (Ad) used as precursor resulted in a large extent of 17betaoxidation of T to Ad (cells: 28-77%; tissues: 35-50%). In malignant liver cell lines, both HA22T and Huh7 cells showed consistent amounts of the 5alpha-reductase enzyme products (18% and 15%, respectively), while 5beta-reductase activity was more pronounced in Huh7 cells (18%) than in HA22T cells (1.8%). Interestingly, a significant extent of estrogen formation could be observed in Huh7 cells (5.4-11.5%), while no aromatase activity could be detected in HA22T cells. In HepG2 cells, along with a relatively high proportion of Ad, estrogens represented the most prominent (50-55%) end product of androgen metabolism, regardless of the precursor used. In liver tissues, equivalent results could be obtained, with a consistent proportion of 17betaoxidation of T to Ad (35-50%) being observed in the majority of samples. However, while normal liver tissue samples exhibited a minor proportion of bioactive androgens (3.4%) with no aromatase products, HCC tissues showed a significant extent of aromatase activity (nearly 20%) with estrogen representing the most prominent metabolic product after 24h incubation with either T or Ad. HCV and alcoholic cirrhotic tissues displayed different patterns of androgen metabolism. The former produced limited amounts of bioactive androgens (5.3%) and considerable levels of the intermediate aromatase product 19OH-Ad (up to 28%), the latter exhibited a prevalence of androgen degradation through the 5beta-reductase pathway (9.8%) and a significant extent of aromatase activity (16% as a whole). In conclusion, three major metabolic states could be depicted, depending on prevalent pathways of androgen metabolism and steroid receptor status: estrogenic, androgenic, and mixed. This model supports the idea that local estrogen biosynthesis may be implicated in human HCC and provides a basis for the exploitation of aromatase inhibitors and/or ER antagonists or selective estrogen receptor modulators (SERMs) as a new therapeutic strategy in HCC patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429435     DOI: 10.1016/j.jsbmb.2009.01.013

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  11 in total

1.  Cyclin D1 regulates hepatic estrogen and androgen metabolism.

Authors:  Lisa K Mullany; Eric A Hanse; Andrea Romano; Charles H Blomquist; J Ian Mason; Bert Delvoux; Chelsea Anttila; Jeffrey H Albrecht
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-25       Impact factor: 4.052

2.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

3.  Transcriptome profiling of HepG2 cells exposed to the flame retardant 9,10-dihydro-9-oxa-10-phosphaphenanthrene 10-oxide (DOPO).

Authors:  Boris V Krivoshiev; Gerrit T S Beemster; Katrien Sprangers; Bart Cuypers; Kris Laukens; Ronny Blust; Steven J Husson
Journal:  Toxicol Res (Camb)       Date:  2018-03-12       Impact factor: 3.524

4.  Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma.

Authors:  Woon-Puay Koh; Jian-Min Yuan; Renwei Wang; Sugantha Govindarajan; Rowena Oppenheimer; Zhen Quan Zhang; Mimi C Yu; Sue Ann Ingles
Journal:  Cancer       Date:  2011-02-11       Impact factor: 6.860

5.  DHEA metabolites activate estrogen receptors alpha and beta.

Authors:  Kristy K Michael Miller; Numan Al-Rayyan; Margarita M Ivanova; Kathleen A Mattingly; Sharon L Ripp; Carolyn M Klinge; Russell A Prough
Journal:  Steroids       Date:  2012-11-02       Impact factor: 2.668

6.  Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone.

Authors:  Luke A Beggs; Joshua F Yarrow; Christine F Conover; John R Meuleman; Darren T Beck; Matthew Morrow; Baiming Zou; Jonathan J Shuster; Stephen E Borst
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-07-29       Impact factor: 4.310

7.  Association of androgen receptor exon 1 CAG repeat length with risk of hepatocellular carcinoma: a case-control study.

Authors:  Kainan Li; Chen Zhong; Jun Wang; Baocheng Wang; Jun He; Jingwang Bi
Journal:  Tumour Biol       Date:  2014-09-14

8.  Aromatase in human liver and its diseases.

Authors:  Shuko Hata; Yasuhiro Miki; Ryoko Saito; Kazuyuki Ishida; Mika Watanabe; Hironobu Sasano
Journal:  Cancer Med       Date:  2013-04-30       Impact factor: 4.452

9.  Estradiol and progesterone exhibit similar patterns of hepatic gene expression regulation in the bovine model.

Authors:  Carla A Piccinato; Guilherme J M Rosa; Alhaji U N'jai; Colin R Jefcoate; Milo C Wiltbank
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

Review 10.  Role of estrogen in hepatocellular carcinoma: is inflammation the key?

Authors:  Liang Shi; Yili Feng; Hui Lin; Rui Ma; Xiujun Cai
Journal:  J Transl Med       Date:  2014-04-08       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.